These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 28235006)

  • 1. Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.
    Simon M; Mesmar F; Helguero L; Williams C
    PLoS One; 2017; 12(2):e0172832. PubMed ID: 28235006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel carbon-11 radiolabeled maternal embryonic leucine zipper kinase inhibitor for PET imaging of triple-negative breast cancer.
    Tang R; Gai Y; Li K; Hu F; Gong C; Wang S; Feng F; Altine B; Hu J; Lan X
    Bioorg Chem; 2021 Feb; 107():104609. PubMed ID: 33454507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [
    Hu F; Gong C; Gai Y; Jiang D; Liu Q; Wang S; Hu M; Pi R; Shu H; Hu J; Lan X
    Mol Pharm; 2021 Sep; 18(9):3544-3552. PubMed ID: 34482695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.
    Kohler RS; Kettelhack H; Knipprath-Mészaros AM; Fedier A; Schoetzau A; Jacob F; Heinzelmann-Schwarz V
    Gynecol Oncol; 2017 Apr; 145(1):159-166. PubMed ID: 28214016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia.
    Zhang Y; Zhou X; Li Y; Xu Y; Lu K; Li P; Wang X
    Oncogene; 2018 Oct; 37(41):5520-5533. PubMed ID: 29895969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploration of MELK as a downstream of Del-1 and druggable targets in triple-negative breast cancer.
    Lee IH; Lee SJ; Kang B; Lee J; Jung JH; Park HY; Park JY; Park NJ; Kim EA; Kang J; Chae YS
    Breast Cancer Res Treat; 2024 May; 205(1):181-191. PubMed ID: 38279017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of MELK produces potential anti-tumour effects in bladder cancer by inducing G1/S cell cycle arrest via the ATM/CHK2/p53 pathway.
    Chen S; Zhou Q; Guo Z; Wang Y; Wang L; Liu X; Lu M; Ju L; Xiao Y; Wang X
    J Cell Mol Med; 2020 Jan; 24(2):1804-1821. PubMed ID: 31821699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases.
    Ji W; Arnst C; Tipton AR; Bekier ME; Taylor WR; Yen TJ; Liu ST
    PLoS One; 2016; 11(4):e0153518. PubMed ID: 27082996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma.
    Bolomsky A; Heusschen R; Schlangen K; Stangelberger K; Muller J; Schreiner W; Zojer N; Caers J; Ludwig H
    Haematologica; 2018 Feb; 103(2):325-335. PubMed ID: 29122991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma.
    Kiseljak-Vassiliades K; Zhang Y; Kar A; Razzaghi R; Xu M; Gowan K; Raeburn CD; Albuja-Cruz M; Jones KL; Somerset H; Fishbein L; Leong S; Wierman ME
    Endocrinology; 2018 Jul; 159(7):2532-2544. PubMed ID: 29790920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
    Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
    Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.
    Morrison CD; Chang JC; Keri RA; Schiemann WP
    Cell Death Dis; 2017 Jun; 8(6):e2899. PubMed ID: 28661474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies.
    Pitner MK; Taliaferro JM; Dalby KN; Bartholomeusz C
    Expert Opin Ther Targets; 2017 Sep; 21(9):849-859. PubMed ID: 28764577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MELK as a potential target to control cell proliferation in triple-negative breast cancer MDA-MB-231 cells.
    Li G; Yang M; Zuo L; Wang MX
    Oncol Lett; 2018 Jun; 15(6):9934-9940. PubMed ID: 29805690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma.
    Maes A; Maes K; Vlummens P; De Raeve H; Devin J; Szablewski V; De Veirman K; Menu E; Moreaux J; Vanderkerken K; De Bruyne E
    Blood Cancer J; 2019 Nov; 9(12):87. PubMed ID: 31740676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth.
    Edupuganti R; Taliaferro JM; Wang Q; Xie X; Cho EJ; Vidhu F; Ren P; Anslyn EV; Bartholomeusz C; Dalby KN
    Bioorg Med Chem; 2017 May; 25(9):2609-2616. PubMed ID: 28351607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis.
    Zaza M; Rashed MH; Elrefaey H; Hassan MH; Abo-Salem OM; El-Sayed ESM
    Can J Physiol Pharmacol; 2024 Jan; 102(1):55-68. PubMed ID: 37818839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MELK promotes Endometrial carcinoma progression via activating mTOR signaling pathway.
    Xu Q; Ge Q; Zhou Y; Yang B; Yang Q; Jiang S; Jiang R; Ai Z; Zhang Z; Teng Y
    EBioMedicine; 2020 Jan; 51():102609. PubMed ID: 31915116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mass spectrometry-based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells.
    McDonald IM; Grant GD; East MP; Gilbert TSK; Wilkerson EM; Goldfarb D; Beri J; Herring LE; Vaziri C; Cook JG; Emanuele MJ; Graves LM
    J Biol Chem; 2020 Feb; 295(8):2359-2374. PubMed ID: 31896573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different mechanisms involved in the berberine-induced antiproliferation effects in triple-negative breast cancer cell lines.
    Lin YS; Chiu YC; Tsai YH; Tsai YF; Wang JY; Tseng LM; Chiu JH
    J Cell Biochem; 2019 Aug; 120(8):13531-13544. PubMed ID: 30957305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.